Emulate, Inc., a Cambridge, MA-based maker of living products for understanding how diseases, medicines, chemicals, and foods affect human health, raised $28m in Series B financing.
Backers included existing investors Hansjörg Wyss, NanoDimension and Cedars-Sinai Medical Center, as well as new investors OS Fund; Atel Ventures; ALS Finding a Cure, a program of the Leandro P. Rizzuto Foundation; and a fourth new unnamed investor.
The company intends to use the funds to accelerate its R&D effort, expedite the launch of its products and expand strategic relationships with industry and academic partners. The proceeds will be used to advance its product design and development across a range of activities, including: the launch of the Human Emulation System as an automated product suite that includes Organ-Chips, instrumentation hardware, and software applications, expansion of the Organ-Chip portfolio to extend beyond the lung, liver, intestine, and skin for additional organs such as kidney, heart, and brain, acceleration of disease-state applications for Organ-Chips, to gain further understanding of mechanisms of diseases in key areas of focus for industry – including neurodegenerative diseases, oncology, intestinal diseases and the microbiome, and infectious diseases.
Led by James Coon, Chief Executive Officer, and Geraldine A. Hamilton, Ph.D., President and Chief Scientific Officer, Emulate has developed proprietary Organs-on-Chips technology which places living human cells in microengineered environments and provides a window into the inner-workings of the body to predict human response to medicines, chemicals and diseases.